


*a transformational approach to precision, personalised particle-beam therapy*



K. Long; 3 October, 2022,  
on behalf of the LhARA collaboration

# The challenge

- Cancer: second most common cause of death globally
  - Radiotherapy indicated in half of all cancer patients
- Significant growth in global demand anticipated:
  - 14.1 million new cases in 2012 → 24.6 million by 2030
  - 8.2 million cancer deaths in 2012 → 13.0 million by 2030
- Scale-up in provision essential:
  - Projections above based on reported cases (i.e. high-income countries)
  - Opportunity: save 26.9 million lives in low/middle income countries by 2035
- Provision on this scale requires:
  - Development of new and novel techniques ... integrated in a
  - Cost-effective system to allow a distributed network of RT facilities

# The LhARA initiative

## Vision:

**Transform clinical practice of proton/ion-beam therapy by creating a fully automated, highly flexible system to harness the unique properties of laser-driven ion beams**

Imperial College  
London

ICR The Institute of  
Cancer Research

Medical  
Research  
Council  
UKRI  
Oxford Institute for  
Radiation Oncology

UNIVERSITY OF  
OXFORD

JAI  
John Adams Institute  
for Accelerator Science



CCAP  
Centre for the Clinical  
Application of Particles

Imperial College  
Academic Health  
Science Centre

CANCER RESEARCH  
UK

IMPERIAL  
CENTRE

NHS  
Imperial College Healthcare  
NHS Trust

MANCHESTER  
1824



UNIVERSITY OF  
BIRMINGHAM



UNIVERSITY OF  
LIVERPOOL

NHS

University Hospitals  
Birmingham  
NHS Foundation Trust

NHS

The Clatterbridge  
Cancer Centre  
NHS Foundation Trust

NHS

The Christie  
NHS Foundation Trust



institut  
Curie



QUEEN'S  
UNIVERSITY  
BELFAST



Swansea  
University  
Prifysgol  
Abertawe

UCL  
MEDICAL PHYSICS  
& BIOMEDICAL  
ENGINEERING



NETHERLANDS  
CANCER  
INSTITUTE  
ANTONI VAN LEEUWENHOEK

HAMPTON UNIVERSITY  
PROTON THERAPY INSTITUTE  
FIGHTING CANCER. SAVING LIVES

University of  
Strathclyde  
Glasgow

DEPARTMENT  
OF PHYSICS

ROYAL  
HOLLOWAY  
UNIVERSITY  
OF LONDON

Lancaster  
University

UNIVERSITY OF  
BIRMINGHAM

CYCLOTRON  
FACILITY

POSITRON  
IMAGING CENTRE

UKRI  
Science and  
Technology  
Facilities Council



ASTeC  
Daresbury Laboratory  
Particle Physics Department  
ISIS Neutron and Muon Source

INFN  
CATANIA



The Cockcroft Institute  
of Accelerator Science and Technology



Corerain  
鯉云科技


LEO  
Cancer Care

MAXER  
Technologies  
Maximum Performance Computing

The Rosalind  
Franklin Institute

NPL  
National Physical Laboratory

# LhARA initiative Programme org chart





# The case for radiobiology

- Relative biological effectiveness:

- Defined relative to reference X-ray beam

- Known to depend on:

- Energy
- Ion species
- Dose
- Dose spatial distribution
- Dose rate
- Tissue type
- Biological endpoint




- Yet:

- All *p*-treatment planning uses RBE = 1.1

- Effective values are used for C<sup>6+</sup>

- Maximise the efficacy of PBT now & in future:

- Systematic programme needed to develop full understanding of radiobiology



# Potential benefit of new regimens

## FLASH


Conventional regime:  $\sim 2$  Gy/min

FLASH regime (p) :  $>40$  Gy/s

Evidence of normal-tissue sparing while tumour-kill probability is maintained:  
i.e. enhanced therapeutic window

## Time line:

- Reports: 2014 (e.g. Flauvaden et al, STM Jul 2014)
- Confirmation in mini-pig & cat: 2018 (Clin. Cancer Research 2018)
- First treatment 2019 (Bourhis et al, Rad.Onc. Oct 2019)




# Potential benefit of new regimens

## Worked example: micro beams

Conventional regime: > 1 cm diameter; homogeneous

Microbeam regime : < 1 mm diameter; no dose between 'doselets'



Remarkable increase of normal rat brain resistance.

[Dilmanian et al. 2006, Prezado et al., Rad. Research 2015]

***Dose escalation in the tumour possible – larger tumour control probability***

# Radiobiology in new regimens

Time domain

Space domain

The ideally flexible beam facility can deliver it all!

⇒ substantial opportunity for a step-change in understanding!

Energy

Ion species

Multidisciplinary approach essential


In combination and with chemo/immuno therapies



# The LhARA collaboration's present mission

Develop LhARA, serving the ITRF, to:

- Explore the vast “terra incognita” of radiation biology
- Prove the feasibility of the laser-hybrid approach
- Lay the foundations for transformative ion-beam therapy
  - Highly automated, patient-specific; implies:
    - Triggerable source
    - Online imaging
    - Integrated fast feedback and control



**LhARA performance summary**

arXiv:2006.00493

	12 MeV Protons	15 MeV Protons	127 MeV Protons	33.4 MeV/u Carbon
Dose per pulse	7.1 Gy	12.8 Gy	15.6 Gy	73.0 Gy
Instantaneous dose rate	$1.0 \times 10^9$ Gy/s	$1.8 \times 10^9$ Gy/s	$3.8 \times 10^8$ Gy/s	$9.7 \times 10^8$ Gy/s
Average dose rate	71 Gy/s	128 Gy/s	156 Gy/s	730 Gy/s


# Laser-hybrid Accelerator for Radiobiological Applications

A novel, hybrid, approach:

- Laser-driven, high-flux proton/ion source
  - Overcome instantaneous dose-rate limitation
    - Capture at >10 MeV
  - Delivers protons or ions in very short pulses
    - Bunches as short as 10—40 ns
  - Triggerable; arbitrary pulse structure
- Novel “electron-plasma-lens” capture & focusing
  - Strong focusing (short focal length) without the use of high-field solenoid
- Fast, flexible, fixed-field post acceleration
  - Variable energy
    - Protons: 15—127 MeV
    - Ions: 5—34 MeV/u


# LhARA Project

## Organisational Breakdown Structure




# Sheath acceleration

- Laser incident on foil target:
  - Drives electrons from material
  - Creates enormous electric field
- Field accelerates protons/ions
  - Dependent on nature of target
- Active development:
  - Laser: power and rep. rate
  - Target material, transport



Schwoerer, H. et al., 2006; Nature, 439(7075).



# Laser-driven beams for radio: example 1

On Draco @ HZDR

DOI: 10.1038/s41598-020-65775-7

- **Draco:**

- **Petawatt laser**

- $E = 13 \text{ J}$ ,  $\tau = 30 \text{ fs}$ ,  $3 \mu\text{m}$  FWHM

- **Beam line:**




- **Target Normal Sheath Acceleration (TNSA)**

- **Pulsed solenoid focusing**

- 19.5T, 2 or 3 pulses/min.
    - S1, S2: 40 mm bore
    - Half angle acceptance  $14^\circ$

- **Measured transmission (18.6 MeV p)**

- 50.6% (dual solenoid)
    - 28.6% (single solenoid)



# Laser-driven beams for radio: example 2

On BELLA @ Berkeley

DOI 10.1038/s41598-022-05181-3

## Berkeley Lab Laser Accelerator (BELLA):

### — Petawatt laser



- $E = 35 \text{ J}$ ,  $\tau = 35 \text{ fs}$ ,  $52 \mu\text{m}$  FWHM

## Beam line:

### — Target Normal Sheath Acceleration (TNSA)


### — Active plasma lens focusing

- 1 mm diameter Ar gas filled capillary
- 33 mm length
- 13 mm behind the tape drive target
- ~0.2% transport efficiency for protons with  $E > 1.5 \text{ MeV}$




# Laser-driven proton/ion source

- Commercial laser:
  - Motivation: risk management



HT Lau  
Thesis, 2022




Smilei)



Ti:Sapphire commercial system > 150 TW  
Pulse ~35 fs at rep-rate of at least 10Hz  
At least 500mJ laser energy -  $I_L \sim 10^{20} \text{ Wcm}^{-2}$

# LhARA Capture

- “Electron-plasma” (Gabor) lens:
  - Strong focusing exploiting electron gas in “Penning/Malmberg” trap



Front. Phys., 29 September 2020; DOI: 10.3389/fphy.2020.567738

# Anomalous Beam Transport through Gabor (Plasma) Lens Prototype

Toby Nonnenmacher <sup>1,\*</sup>, Titus-Stefan Dascalu <sup>1,\*</sup>, Robert Bingham <sup>2,3</sup>, Chung Lim Cheung <sup>1</sup>, Hin-Tung Lau <sup>1</sup>, Ken Long <sup>3,4</sup>, Jürgen Pozimski <sup>3,4</sup> and Colin Whyte <sup>2</sup>

- <sup>1</sup> Department of Physics, Imperial College London, Exhibition Road, London SW7 2AZ, UK; chung.cheung14@imperial.ac.uk (C.L.C.); h.lau17@imperial.ac.uk (H.T.L.)
  - <sup>2</sup> Department of Physics, SUPA, University of Strathclyde, 16 Richmond Street, Glasgow G4 0NG, UK; bob.bingham@strath.ac.uk (R.B.); colin.whyte@strath.ac.uk (C.W.)
  - <sup>3</sup> STFC Rutherford Appleton Laboratory, Harwell Oxford, Didcot OX11 0QX, UK; k.long@imperial.ac.uk (K.L.); j.pozimski@imperial.ac.uk (J.P.)
  - <sup>4</sup> John Adams Institute for Accelerator Science, Imperial College London, London SW7 2AZ, UK
- \* Correspondence: toby.nonnenmacher14@imperial.ac.uk (T.N.); t.dascalu19@imperial.ac.uk (T.S.D.)

**Abstract:** An electron plasma lens is a cost-effective, compact, strong-focusing element that can ensure efficient capture of low-energy proton and ion beams from laser-driven sources. A Gabor lens prototype was built for high electron density operation at Imperial College London. The parameters of the stable operation regime of the lens and its performance during a beam test with 1.4 MeV protons are reported here. Narrow pencil beams were imaged on a scintillator screen 67 cm downstream of the lens. The lens converted the pencil beams into rings that show position-dependent shape and intensity modulation that are dependent on the settings of the lens. Characterisation of the focusing effect suggests that the plasma column exhibited an off-axis rotation similar to the  $m = 1$  diocotron instability. The association of the instability with the cause of the rings was investigated using particle tracking simulations.

**Keywords:** plasma trap; space-charge lens; beam transport; instability; proton therapy

## 1. Introduction

One of the principal challenges that must be addressed to deliver high-flux pulsed proton or positive-ion beams for many applications is the efficient capture of the ions ejected from the source. A typical source produces protons with kinetic energies of approximately 60 keV [1–3] and ions with kinetic energies typically below 120 keV [4,5]. At this low energy the mutual repulsion of the ions causes the beam to diverge rapidly. Capturing a large fraction of this divergent flux therefore requires a focusing element of short focal length. Proton- and ion-capture systems in use today employ magnetic, electrostatic, or radio frequency quadrupoles, or solenoid magnets to capture and focus the beam [2,6–8].

Laser-driven proton and ion sources are disruptive technologies that offer enormous potential to serve future high-flux, pulsed beam facilities [9–16]. Possible applications include proton- and ion-beam production for research, particle-beam therapy, radio-nuclide production, and ion implantation. Recent measurements have demonstrated the laser-driven production of large ion fluxes at kinetic energies in excess of 10 MeV [17–20]. The further development of present technologies and the introduction of novel techniques [21,22] makes it conceivable that significantly higher ion energies will be produced in the future [13,23,24]. By capturing the laser-driven ions at energies two orders of magnitude greater than those pertaining to conventional sources, it will be possible to evade the current space-charge limit on the instantaneous proton and ion flux that can be delivered. While in some situations the high divergence of laser-driven ion beams can be reduced [25,26], for the tape-drive targets proposed for medical beams [16,20] it necessary to capture the beam using a strong-focusing element as close to the ion-production point as possible.



Citation: Nonnenmacher, T.; Dascalu, T.S.; Bingham, R.; Cheung, C.L.; Lau, H.T.; Long, K.; Pozimski, J.; Whyte, C. Anomalous Beam Transport through Gabor (Plasma) Lens Prototype. *Appl. Sci.* **2021**, *11*, 4357. <https://doi.org/10.3390/app11104357>


Academic Editor: Paolo Branchini

Received: 13 April 2021  
Accepted: 4 May 2021  
Published: 11 May 2021

**Publisher's Note:** MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.




Copyright © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).



**VSIM/BDSIM:**  
evaluation of  $m = 1$   
diocotron mode

Dascalu

# Beam envelopes Stage 1




HT Lau, IPAC 2021, WEPAB139



- Propagation of “semi-realistic” source distribution:
  - Generated using SMILEI
  - Optimisation studies on going

# Rapid, flexible acceleration for stage 2

- **Fixed-field alternating-gradient accelerator (FFA):**
  - **Invented in 1950s**
    - Kolomensky, Okhawa, Symon
  - **Compact, flexible solution:**
    - Multiple ion species
    - Variable energy extraction
    - High repetition rate (rapid acceleration)
    - Large acceptance
  - **Successfully demonstrated:**
    - Proof of principle at KEK
    - Machines at KURNS
    - Non-scaling PoFP EMMA (DL)



Evolution of RACCAM design; prototype magnet demonstrated




# LhARA @ the Ion Therapy Research Facility

J. Clark, M. Noro, A. Woodcock


14Jun21

## Ion Therapy Research Facility



### 1. Schematic diagram of the Ion Therapy Research Facility



### 2. ITRF development timeline



### 3. Institutes that make up the ITRF collaboration



Submitted to UKRI Infrastructure Advisory Committee  
14 June 2021


# Proposal for LhARA contributions to Preliminary Activity and ITRF Preconstruction Phase

J. Clark, M. Noro, A. Woodcock


14Jun21

## Ion Therapy Research Facility

### 1. Schematic diagram of the Ion Therapy Research Facility



### 2. ITRF development timeline



### 3. Institutes that make up the ITRF collaboration



## Finalised 01Jun22: CCAP-TN-10

June 1, 2022

CCAP-TN-10 (2022)



### The Laser-hybrid Accelerator for Radiobiological Applications R&D proposal for the preliminary, pre-construction phases

The LhARA collaboration

P. Allport<sup>1</sup>, A. Aymar<sup>2</sup>, C. J. Baker<sup>3</sup>, J. Bamber<sup>4</sup>, P. Beard<sup>5</sup>, T. Becker<sup>6</sup>, S. Benson<sup>7</sup>, A. Beqiri<sup>8</sup>, W. Bertsche<sup>9,10</sup>, R. Bingham<sup>11,12</sup>, N. Bliss<sup>13</sup>, E. Boella<sup>14,10</sup>, S. Boogert<sup>15,16</sup>, M. Borghesi<sup>17</sup>, P.N. Burrows<sup>18,19</sup>, A. Carabe<sup>20,21</sup>, M. Charlton<sup>3</sup>, J. Clarke<sup>13</sup>, B. Cox<sup>3</sup>, T.S. Dascalu<sup>22</sup>, M. Dosanjh<sup>23,18</sup>, N.P. Dover<sup>24,22</sup>, S. Eriksson<sup>3</sup>, O.C. Ettlinger<sup>24,22</sup>, A. Giacca<sup>25,26</sup>, S. Gibson<sup>15,16</sup>, R. Gray<sup>11</sup>, S. Green<sup>27</sup>, T. Greenshaw<sup>28</sup>, D. Gujra<sup>29</sup>, H.C. Hall<sup>30</sup>, E.M. Hammond<sup>30</sup>, C. Hardiman<sup>31</sup>, E.J. Harris<sup>4</sup>, L. Holland<sup>32</sup>, A. Howard<sup>33</sup>, W.G. Jones<sup>34,35</sup>, K.J. Kirby<sup>35,34</sup>, A. Kirkland<sup>32,33</sup>, A. Knoll<sup>36</sup>, T. Kokalova<sup>3</sup>, D. Kordopati<sup>34</sup>, T.J. Kuo<sup>37</sup>, A. Kurup<sup>32,2</sup>, J.B. Lagrange<sup>2</sup>, H.T. Lau<sup>38</sup>, K.R. Long<sup>24,22,37</sup>, W. Luk<sup>36</sup>, A.E. Macintosh-LaRocque<sup>34</sup>, R. Mamutov<sup>39,40</sup>, T. Masler<sup>41,42</sup>, J. Matheson<sup>37</sup>, M. Maxouti<sup>42,37</sup>, J.M. McGarrigle<sup>44,41</sup>, P. McKenna<sup>11,43</sup>, R. McLaughlan<sup>11,24</sup>, I. McNeish<sup>44</sup>, M. Merchant<sup>33</sup>, Z. Najmudin<sup>44,22</sup>, S.R. O'Neill<sup>14</sup>, U. Oefke<sup>6</sup>, H. Owen<sup>13</sup>, C. Palmer<sup>17</sup>, J.L. Parsons<sup>45,46</sup>, J. Pasternak<sup>22,2</sup>, H. Poptani<sup>47</sup>, J. Pozimski<sup>24,22,2</sup>, Y. Prezado<sup>41,42</sup>, P. Price<sup>44</sup>, T. Price<sup>4</sup>, K.M. Prise<sup>48</sup>, P.P. Rajeev<sup>12</sup>, P. Ratoff<sup>14,10</sup>, C. Rogers<sup>4</sup>, F. Romano<sup>49</sup>, G. Schettino<sup>50,51</sup>, W. Shields<sup>15</sup>, R.A. Smith<sup>24</sup>, D. Spiers<sup>11,43</sup>, R. Taylor<sup>22</sup>, J. Thomson<sup>2</sup>, S. Towse<sup>52</sup>, P. Weightman<sup>26</sup>, C.P. Welsh<sup>25,10</sup>, C. Wheldon<sup>1</sup>, C. Whyte<sup>11,43</sup>, R. Xiac<sup>53</sup>

<sup>1</sup> School of Physics and Astronomy, University of Birmingham, Edgbaston, Birmingham, B15 2TT, UK  
<sup>2</sup> ISIS Neutron and Muon Source, STFC Rutherford Appleton Laboratory, Harwell Oxford, Didcot OX11 0QX UK  
<sup>3</sup> Department of Physics, Faculty of Science and Engineering, Swansea University, Singleton Park, Swansea, SA2 8PP  
<sup>4</sup> The Institute of Cancer Research, 123 Old Brompton Road, London, SW7 3BP, UK  
<sup>5</sup> Dept of Medical Physics and Biomedical Engineering, University College London, WC1E 6BT, UK  
<sup>6</sup> Maxler Technologies Limited, 3 Hamme Smith Grove, London W6JH3, UK  
<sup>7</sup> Department of Radiology, Netherlands Cancer Institute-Antoni Van Leeuwenhoek, Amsterdam, The Netherlands  
<sup>8</sup> Faculty of Mechanical Engineering, Ss. Cyril and Methodius University, Rugar Bozhovik, Skopje 1000, Republic of North Macedonia  
<sup>9</sup> Department of Physics and Astronomy, The University of Manchester, Oxford Rd, Manchester, M13 9PL UK  
<sup>10</sup> Cockcroft Institute, Daresbury Laboratory, Sci-Tech Daresbury, Keckwick Ln, Daresbury, Warrington UK  
<sup>11</sup> Department of Physics, STFC Rutherford Appleton Laboratory, Harwell Oxford, Didcot OX11 0QX, UK  
<sup>12</sup> STFC Daresbury Laboratory, Daresbury, Cheshire, W44 4AD, UK  
<sup>13</sup> Department of Physics, Lancaster University, Bailrigg, Lancaster LA1 4YW, UK  
<sup>14</sup> Department of Physics, Royal Holloway University of London, Egham, Surrey, TW20 0EX, UK  
<sup>15</sup> John Adams Institute, Department of Physics, Royal Holloway, University of London, Egham, TW20 0EX, UK  
<sup>16</sup> School of Mathematics and Physics, Queen's University Belfast, University Road, Belfast, BT7 1NN, Northern Ireland, UK  
<sup>17</sup> John Adams Institute, University of Oxford, Keble Rd, Oxford, OX1 3FH  
<sup>18</sup> Particle Physics, Derys Wilkinson Building, Keble Rd, Oxford, OX1 3FH  
<sup>19</sup> Department of Medical Physics, Hampton University Proton Therapy Institute, Hampton, VA 23666 Hampton University  
<sup>20</sup> John Adams Institute for Accelerator Science, Imperial College London, London SW7 2AZ, UK  
<sup>21</sup> DG Unit, CERN, CH-1211 Geneva 23, Switzerland




To serve ITRF: 2 + 3-year project in 6 work packages:

1. Project Management
2. Laser-driven proton and ion source
3. Proton and ion capture
4. Real-time dose-deposition profiling
5. Novel, automated, end-station development
6. Facility design and integration


Requested resources for 2-year preliminary phase; Identified need for further 3-year preconstruction phase




**Novel accelerator techniques**



**System: image processing  
fast feedback, control**



**Fundamental  
biology & biochemistry**



# Conclusions


- Laser-driven sources are disruptive technologies ...
  - With the potential to drive a step-change in clinical capability
- Laser-hybrid approach has potential to:
  - Overcome dose-rate limitations of present PBT sources
  - Deliver uniquely flexible facility:
    - Range of: ion species; energy; dose; dose-rate; time; and spatial distribution
  - Be used in automated, triggerable system → reduce requirement for large gantry
    - Disruptive/transformational approach to “distributed PBT for 2050”
- By serving the ITRF, the LhARA collaboration now seeks to:
  - Prove the novel laser-hybrid systems in operation
  - Contribute to the study of the biophysics of charged-particle beams
    - Enhance treatment planning
  - Create novel capabilities to ‘spin back in’ to science and innovation



**Novel accelerator techniques**

**System: image processing  
fast feedback, control**

**Fundamental  
Biology & biochemistry**






# Hadron beams for radiation therapy



Robert R. Wilson

Radiology 47:487-91 (1946)


in tissue is 12 cm., while  
 ev proton is 27 cm. It is  
 protons can penetrate to  
 body.  
 ceeds through the tissue  
 straight line, and the tissue  
 of unit density, *i.e.*, 15  
 and 85 per cent water.  
 can be easily extended to  
 and densities.<sup>2</sup> The accu  
 per cent. However, exa  
 ious tissues can be quic



- Wilson, then at Harvard designing 150 MeV cyclotron:
  - Identified benefits and properties of proton beams for RT
  - Pointed out potential of ions (carbon) and electrons


# Particle beam therapy today

Cyclotron based




Christie Hospital Manchester

Synchrotron based



# Evolving state of the art



Cancer therapy  
(Mass Gen Hosp)  
1974

Clinical studies  
(pituitary gland);  
1954

Biological studies;  
1948

Synchrotron  
Goward, Barnes; 1946

Cyclotron  
Laurence; 1932

# Many initiatives in Americas, Europe, Asia

Applications in biological research, ambition to push toward clinical application ...

Phys Lett A. (2002) 299:240–7. doi: 10.1016/S0375-9601(02)00521-2

Med Phys. (2003) 30:1660–70. doi: 10.1118/1.1586268

Med Phys. (2004) 31:1587–92. doi: 10.1118/1.1747751

Science. (2003) 300:1107–111

New J Phys. (2010) 12:85003. doi: 10.1088/1367-2630/12/8/085003

Phys Med Biol. (2011) 56:6969–82. doi: 10.1088/0031-9155/56/21/013

Appl Phys Lett. (2011) 98:053701. doi: 10.1063/1.3551623

Appl Phys Lett. (2012) 101:243701. doi: 10.1063/1.4769372

AIP Adv. (2012) 2:011209. doi: 10.1063/1.3699063

Appl Phys B. (2013) 110:437–44. doi: 10.1007/s00340-012-5275-3

Appl Phys B. (2014) 117:41–52. doi: 10.1007/s00340-014-5796-z

Radiat Res. (2014) 181:177–83. doi: 10.1667/RR13464.1

Phys Rev Accel Beams. (2017) 20:1–10. doi: 10.1103/PhysRevAccelBeams.20.032801

J Instrum. (2017) 12:C03084. doi: 10.1088/1748-0221/12/03/C03084

A-SAIL Project. (2020). Available online at: <https://www.qub.ac.uk/research-centres/A-SAILProject/>

Vol. 8779. Prague: International Society for Optics and Photonics. SPIE (2013). p. 216–25.

Vol. 11036. International Society for Optics and Photonics. SPIE (2019). p. 93–103.

Nuovo Cim C. (2020) 43:15. doi: 10.1393/ncc/i2020-20015-6

10th International Particle Accelerator Conference. Melbourne, VIC (2019). p. TUPTS005

...

I will not attempt a review, choosing instead to focus on opportunity

## Variety of initiatives; some key examples

### On PHELIX @ GSI

DOI: 10.1063/1.3299391



DOI: 10.1103/PhysRevSTAB.14.121301

DOI: 10.1103/PhysRevSTAB.16.101302

DOI: 10.1103/PhysRevSTAB.17.031302

NIMA 909 (2018) 173–176

- **PHELIX:**
  - **Petawatt High-Energy Laser for Heavy Ion EXperiments**
    - $E < 25 \text{ J}$ ,  $\tau = 500 \text{ fs}$ ,  $I > 10^{19} \text{ J/cm}^2$
- **LIGHT:**
  - **Target Normal Sheath Acceleration (TNSA)**
  - **Ion beam is collimated by a pulsed high-field solenoid**
  - **Phase rotation in RF cavity**
  - **Final focus with a second pulsed high-field solenoid**



Variety of initiatives; some key examples

## On CLAPA @ Peking University

DOI: 10.1103/PhysRevAccelBeams.22.061302

DOI: 10.1103/PhysRevAccelBeams.23.121304

- **Compact Laser Plasma Accelerator (CLAPA):**

- **Petawatt laser**

- $E = 1.3 \text{ J}$ ,  $\tau = 30 \text{ fs}$ ,  $5 \mu\text{m FWHM}$

- **Beam line:**

- **Target Normal Sheath Acceleration (TNSA)**



- **Quadrupole triplet focusing**

TABLE I. The CLAPA beam line parameters.


Type	Length	Aperture	Max B	# turns	Current
Q1	100 mm	30 mm	5 KGs/cm	16	300 A
Q2	200 mm	64 mm	2.5 KGs/cm	20	540 A
Q3	100 mm	64 mm	2.5 KGs/cm	20	540 A

- **Measured transmission:**

- **88% transmission through triplet**
    - **$\pm 50 \text{ mrad}$  collection angle @ 5 MeV**




## Experimental Hall 4 ELIMAIA Ion Acceleration



# ELIMAIA-ELIMED

Quantum Beam Sci. 2018, 2, 8; doi:10.3390/qubs2020008  
Frontiers in Phys. Med. Phys. & Imag. – doi: 10.3389/fphy.2020.564907



Extreme Light Infrastructure, Prague, Czech Republic:

- **ELI Multidisciplinary Applications of laser-Ion Acceleration (ELIMAIA)**
  - **ELI MEDical and multidisciplinary applications (ELIMED)**
    - **ELIMAIA section dedicated to ion focusing, selection, characterization, and irradiation**
  - **Proton energies from 5 to 250 MeV transported to in-air section**

